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1. Introdution 
Diabetes and its devastating complications reduce life expectancy and adversely affect 
quality of life amongst those affected, thus, posing immense challenges to many societal 
sectors. The upsurge in the prevalence of diabetes from 171 million in 2000 to 366 million by 
2030 as projected by the World Health Organization threatens to overwhelm the economic 
and healthcare system globally.  
In type 1 diabetes the prevalence gradually increases from onset of disease (6% after 1–3 
years), reaching over 50% after 20 years [Warram, 1996]. In type 2 diabetes the prevalence is 
20–25% in both newly diagnosed and established diabetes [Mogensen, 1994]. Approximately 
40% of patients with type 1 diabetes and 20 to 40% of those with type 2 diabetes will 
eventually develop diabetic nephropathy, although the reason why not all patients with 
diabetes develop this complication is unknown.  
In both types of diabetes, chronic hyperglycemia is the primary cause of the disease. In type 
1 diabetes hyperglycemia starts in the first decades of life and is usually the only recognized 
cause of nephropathy. On the contrary, in type 2 diabetes  hyperglycemia starts after the 
forties, usually when the kidneys have already suffered the long‐term consequences of 
ageing and of other recognized promoters of chronic renal injury such as arterial 
hypertension, obesity, dyslipidemia, and smoking [Ruggenenti, 2000]. Similar histological 
and clinical courses in all diabetic individuals indicated that the pathogenesis of 
nephropathy is similar in patients with type 1 and type 2 diabetes mellitus. 
The kidney is an extremely complex organ with broad ranging functions in the body, 
including, but not restricted to, waste excretion, ion and water balance, maintenance of blood 
pressure, glucose homeostasis and generation of erythropoietin or activation of vitamin D. 
With diabetes, many of these integral processes are interrupted via a combination of 
hemodynamic and metabolic changes; hyperglycemia also activates a series of changes leading 
to glomerular and tubular dysfunction and accelerates glomerular cell apoptosis [Forbes, 
2010]. Different pathogenetic, hemodynamic and metabolic processes can lead to diabetic 
kidney disease. In recent years, great progress has been made in understanding the risk factors 
and pathogenetic processes in diabetic nephropathy. In addition, new insight into the 
pathophysiology of this chronic disease has lead to better preventive therapies, treatment 
possibilities and reduced progression to end stage renal disease. 
Diabetic kidney disease refers to a characteristic set of structural and functional kidney 
abnormalities in patients with diabetes. Classic glomerulosclerosis is characterized by 
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increased glomerular basement membrane width, diffuse mesangial sclerosis, hyalinosis, 
microaneurysm, and hyaline arteriosclerosis [Mauer, 1981]. The structural abnormalities 
include hypertrophy of the kidney, increase in glomerular basement membrane thickness, 
nodular and diffuse glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The 
functional alterations include an early increase in glomerular filtration rate with 
intraglomerular hypertension, subsequent proteinuria, systemic hypertension, and eventual 
loss of renal function [Ayodele - 2004].  
The management of patients with type 2 diabetes and progressive kidney disease requires a 
comprehensive approach that includes aggressive blood pressure control with agents that 
also lower urinary protein excretion and optimization of glucose and lipid control, 
considering the therapeutic limitations imparted by renal dysfunction. Clinicians must also 
address the comorbidities associated with renal failure such as anemia and secondary 
hyperparathyroidism. Diabetic nephropathy typically follows a slowly progressive course 
from albuminuria to azotemia. Consequently, optimal care includes planning for the 
management of impending renal failure long before the patient requires dialysis or 
transplantation. 
The aim of this chapter is to provide a comprehensive review about the risk factors, the 
histological changes and the pathogenic mechanisms that lead to diabetic 
nephropathy/diabetes kidney disease, diagnosis, new biomarkers and recent developments 
in the prevention and treatment of diabetes kidney disease, targeting the main risk factors 
and resulting in renal protection and reduced disease progression. 
2. Diabetic nephropathy or diabetic kidney disease?  
The phenomenon of albuminuria has been recognized for more than 200 yr, and its association 
with kidney disease dates to the epochal insights of Richard Bright in 1827 [Cameron, 1988]. 
The presence of microalbuminuria is associated with increased cardiovascular morbidity and 
mortality, and regular screening is recommended in guidelines for diabetes care. Albuminuria 
reflects functional and potentially reversible abnormalities initiated by glomerular 
hyperfiltration, proteinuria, a size-selective dysfunction of the glomerular barrier normally 
associated with glomerular filtration rate (GFR) decline that may result in end-stage renal 
disease [Ruggenenti, 2006].  
The Diabetes and Chronic Kidney Disease work group of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative suggested that chronic kidney disease 
considered to be caused by diabetes should be named "diabetic kidney disease" and the term 
"diabetic nephropathy" should be reserved for kidney disease attributed to diabetes with 
histopathological changes, demonstrated by renal biopsy [Cavanaugh - 2007]. Progression 
from normoalbuminuria to microalbuminuria defines the initiation of diabetic nephropathy, 
and the transition from microalbuminuria to overt diabetic nephropathy resulting in 
deterioration of renal function and end-stage renal disease constitutes its progression.  
Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 
μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive 
decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an 
increased risk for cardiovascular morbidity and mortality. 
3. The initiation of diabetic kidney disease 
Generalized endothelial dysfunction and inflammation are important antecedents of 
microalbuminuria in both types of diabetes. Markers of endothelial dysfunction, including 
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elevated serum von Willebrand factor (vWF) and increased transcapillary albumin escape 
rate, are present before the onset of microalbuminuria in type 1 diabetes and worsen in 
association with it. Type 2 diabetes is often complicated by the presence of other risk factors 
for vascular disease, and discerning the contribution of hyperglycemia and its sequel to 
endothelial dysfunction in this condition is more difficult [Satchell, 2008]. While in some 
type 2 diabetic patients microalbuminuria may occur in the absence of evidence of 
endothelial dysfunction, in others, vWF levels predict its development [Stehouwer, 2002]. 
Markers of chronic low-grade inflammation, including C-reactive protein (CRP), are also 
correlated with microalbuminuria in type 1 and type 2 diabetes [Schalkwijk, 1999]. 
4. The natural progression of diabetic kidney disease 
In an initial phase, diabetic kidney disease is characterized by glomerular hyperfiltration 
due to a reduction in the resistance of the afferent and efferent glomerular arterioles, and 
consequent increased renal perfusion. The natural progression of diabetic nephropathy has 
been well studied in type 1 diabetes by Mogenson et al. There are 5 stages of diabetic kidney 
disease: 
Stage 1: Stage of hyperfiltration is characterized by renal hypertrophy and renal hyperfiltration. 
Increased glomerular filtration leads to increased urinary albumin excretion rate (increases by 
20- 40 percent) along with increase in renal blood flow by 9 -14 percent.  
Stage 2: Renal hyperfiltration with increased glomerular filtration pressure persists, but there 
is normalization of urinary albumin excretion rate and normal blood pressure.  
Stage 3: Incipient nephropathy or stage of microalbuminuria is characterised by urinary albumin 
excretion rate of 30 -300 mg per day, with a rise of blood pressure. More characteristic is the 
impaired nocturnal dip in blood pressure. Microscopically, the renal biopsy (or histology) 
shows increased basement membrane thickness and increased mesangium.  
Stage 4: Overt nephropathy is characterized by progressive drop in glomerular filtration rate 
by 10 ml per minute per year, while proteinuria increases at the rate of 15 – 40 percent per 
year and hypertension ensues.  
Stage 5: End stage renal disease occurs at about 7 -14 years from stage 4 requiring renal 
replacement therapy. 
However, it is often difficult to document these various stages in a diabetic patient in clinical 
practice because of confounding factors, such as blood pressure medications, which modify 
the natural course of diabetic nephropathy. 
A greater proportion of patients with type-2 diabetes compared with type-I diabetes have 
microalbuminuria and overt nephropathy at or shortly after diagnosis of diabetes. This is 
because the disease may have been present for several years before the diagnosis. In addition, 
concomitant presence of hypertension at the time of diagnosis also contributes to the high 
prevalence of microalbuminuria in type-2 diabetes. Progression from microalbuminuria to 
overt nephropathy occurs in 20-40% of Caucasians within a 10-year period, with 
approximately 20% of those with overt nephropathy progressing to ESRD over a period of 20 
years [Ayodele, 2004]. 
5. Epidemiology 
Diabetic kidney disease is one of the most serious complications of diabetes mellitus and is 
the leading cause of end stage renal disease both in the USA and in Europe, requiring renal 
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replacement therapy. As the population of patients with diabetes of long duration grows, 
reports of a dramatically increasing burden of diabetic nephropathy are appearing. Globally 
the burden of diabetes is expected to double between 2000 and 2030, with the greatest 
increases in prevalence expected to occur in the Middle East, sub-Saharan Africa, and India 
(KDOQI Clinical Practice Guidelines). This increased risk and more rapid progression of 
diabetic nephropathy also has been reported in immigrants from developing to developed 
countries (KDOQI Clinical Practice Guidelines) [Burney, 2009].  
Diabetic kidney disease affects males and females equally and rarely develops before 10 
years’ duration of type 1 DM. The peak incidence (3%/year) is usually found in persons 
who have had diabetes for 10-20 years. The mean age of patients who reach end-stage 
kidney disease is about 60 years. Although in general, the incidence of diabetic nephropathy 
is higher among elderly persons who have had type 2 diabetes for a longer period, the role 
of age in the development of diabetic kidney disease is unclear. In Pima Indians with type 2 
diabetes, the onset of diabetes at a younger age was associated with a higher risk of 
progression to end-stage kidney disease.  
6. Risk factors 
Although diabetes is often accompanied by hyperglycemia, hypertension, and altered lipid 
profile, surprisingly, most individuals with type 1 or type 2 diabetes do not develop diabetic 
nephropathy. This suggests that other factors are involved [Hall, 2006]. Persuasive 
evidences have implicated also nontraditional risk factors including lipid disorders, chronic 
inflammation and anemia in the development of diabetic kidney disease. 
6.1 Race 
The incidence and severity of diabetic kidney disease are increased in blacks, Mexican 
Americans, Pima Indians, and Hispanics compared with Caucasians. Even after adjusting 
for confounding factors such as lower socioeconomic status and increased incidence of 
hypertension in blacks, there is still a 4.8 times greater risk of ESRD in blacks compared to 
Caucasians [Ayodele, 2004]. 
6.2 Aging 
Ageing is per se a cause of progressive glomerulosclerosis and combined with the risk factors 
may contribute to the specific arteriolosclerotic changes, that often coexist with, and 
occasionally overwhelm, the typical features of diabetic glomerulopathy, in particular in 
type 2 diabetes [Ruggeneti, 1998]. Renal blood flow and GFR diminish over time in elderly 
persons, minimized by a rise in the filtration fraction. In older diabetic patients, the decrease 
in kidney mass, particularly the renal cortex, and the histological changes of diabetic 
nephropathy are compounded by advanced vascular changes. Pathologically, the aging 
kidney may be associated with basement membrane thickening and mesangial expansion 
that are also key histological features of diabetic glomerulopathy. Global glomerulosclerosis 
affecting the kidneys of elderly persons may relate to hyperperfusion, also observed in 
diabetes. However, studies about the diagnosis and prevalence of diabetic kidney disease in 
the elderly are lacking [Williams, 2009]. 
6.3 Smoking 
Smoking is a risk factor for diabetic nephropathy and might contribute to its progression 
[64]. Although some studies did not confirm these observations, it is strongly recommended 
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to quit smoking in any phase of DN, also aiming to reduce the associated cardiovascular 
and cancer risk [Luk, 2008]. 
6.4 Genetic risk factors 
Genetic susceptibility is one of the determinants of progression and severity in diabetic 
kidney disease. Several genes predisposing to type 2 diabetes have recently been identified. 
In addition to the recognized and powerful effects of environmental factors, there is 
abundant evidence in support of genetic susceptibility to the microvascular complication of 
nephropathy in individuals with both type 1 and type 2 diabetes. Familial aggregation of 
phenotypes such as end-stage renal disease, albuminuria, and chronic kidney disease have 
routinely been reported in populations throughout the world, and heritability estimates for 
albuminuria and glomerular filtration rate demonstrate strong contributions of inherited 
factors. Recent genome-wide linkage scans have identified several chromosomal regions 
that likely contain diabetic nephropathy susceptibility genes, and association analyses have 
evaluated positional candidate genes under these linkage peaks. These complimentary 
approaches have demonstrated that polymorphisms in the carnosinase 1 gene on 
chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 
7p are likely associated with susceptibility to diabetic nephropathy [Freedman - 2007]. 
6.5 Arterial hypertension 
Increase of arterial blood pressure is an early and frequent phenomenon in diabetic 
nephropathy as well as in the development of macrovascular lesions. There has been some 
recent evidence that genetic predisposition to hypertension may predispose to the 
development of diabetic kidney disease. In diabetic kidney disease hypertension is not 
merely the result of relentless kidney damage. There is considerable clinical evidence that 
the elevated arterial pressure is also important in the genesis of the glomerular lesion. 
Indeed the development of proteinuria is paralleled in most cases by a gradual increase in 
systemic blood pressure, and there is a significant correlation between the blood pressure 
levels and the rate of decline in glomerular filtration rate [Mogensen, 1985]. In type 2 
diabetes, lowering blood pressure, regardless of the used agent, retards the onset and 
progression of diabetic nephropathy [Schrier, 2002]. In type 1 diabetes, Lurbe et al. have 
noted that an insufficient decline in nighttime blood pressure (nondipping) preceded the 
onset of microalbuminuria [Lurbe, 2002]. Although the type 2 diabetic patient is usually 
hypertensive before the onset of nephropathy, nephropathy aggravates the severity of 
hypertension. 
6.6 Hyperglycemia 
The hyperglycemic state itself is a strong risk factor for diabetic kidney disease and causes 
the proliferation of mesangial cells and their matrix, as well as the thickening of the 
basement membrane. In recent years, many discoveries elucidated the mechanisms by 
which hyperglycemia affect the renal glomerular and tubulointerstitial cells and suggested 
that podocyte injury have a pivotal role in the pathogenesis of diabetic glomerulopathy. 
Molecular pathogenesis of diabetic podocyte injury is likely multifactorial involving a 
number of interrelated signaling pathways that have yet to be well understood. Sustained 
hyperglycemia affects the glomerular cells by various mechanisms. The changes lead to 
altered structure and function in the glomerulus.  
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6.7 Lipid disorders 
Patients with diabetes have a variety of disorders of plasma lipids. These lipid abnormalities 
are known to contribute to cardiovascular risk. The role of lipids in diabetic nephropathy is 
not clear [Hall, 2006]. In type 2 DM, elevated serum cholesterol is a risk factor for the 
development of DN. In type 1 DM patients increased serum triglycerides, total and LDL-
cholesterol were associated with micro- and macroalbuminuria. High serum cholesterol also 
seems to be a risk factor for GFR loss in macroalbuminuric type 1 diabetic subjects [ 
Zelmanovitz - 2009]. 
For many decades, obesity has been known to cause structural changes to the renal 
parenchyma, and biopsies from obese subjects consistently showed glomerulomegaly with 
or without focal segmental glomerulosclerosis. Several mechanisms have been proposed to 
explain obesity-related renal changes. One explanation is the greater work load imposed on 
the kidneys as a direct result of larger body mass, as increased tissue turnover and toxic 
output place additional strains on the nephrons. Another hypothesis is lipotoxicity: the 
exposure of renal tissues to excess free fatty acid leads to generation of oxidative stress and 
cytotoxic lipid products. Recent attention has focused on adipose tissue as a rich source of 
pro-inflammatory cytokines and growth factors such as tumor necrosis factor a, interleukin-
6 and leptin. The plethora of circulating cytokines is believed to have direct effects on renal 
hemodynamics and glomerular cellularity [Luk, 2008]. 
Ravid et al. found that the level of cholesterol both at onset and after a five-year follow-up 
period was positively related with the subsequent increase in urinary albumin excretion in 
microalbuminuric patients with type-2 diabetes [Ravid, 1995]. Gall et al. found that total 
serum cholesterol was significantly associated with development of abnormally increased 
urinary albumin excretion [Gall, 1997]. Klein et al. in a study of type-I individuals, found 
that higher total serum cholesterol and lower HDL cholesterol were associated with 
incidence of renal insufficiency [Klein, 1999]. 
6.8 Increased protein intake 
Protein intake: 0.8 – 1.0 gram per kilogram body weight per day in patients with normal 
renal functions and decrease to 0.6-0.8 gram per kilogram body weight per day once 
proteinuria sets in. High intakes of animal protein have been shown to increase renal blood 
flow and glomerular filtration rate (GFR) whereas soy protein does not appear to have this 
effect. Substituting soy protein for animal protein has been found to decrease hyperfiltration 
in subjects with diabetes and may reduce urine albumin excretion [Song, 2004]. 
6.9 Chronic inflammation 
With the recognition of the central role played by inflammatory processes in cardiovascular 
disease and both type 1 and type 2 diabetes, the association between potentially modifiable 
inflammatory biomarkers and clinical outcomes such as nephropathy and cardiovascular 
disease in diabetes is of interest. Moreover, although diabetic nephropathy has traditionally 
not been considered an inflammatory nephritis, more recent evidence that macrophage 
accumulation is characteristic for diabetic glomerulosclerosis has challenged this perception 
[Foruta, 1993].  
Recent studies suggested that inflammatory processes and immune cells might be involved 
in the development and progression of diabetic nephropathy. Infiltrated macrophages are 
found within renal diabetic tissues, and recent studies demonstrated that macrophage-
derived products can induce further inflammation in the diabetic kidney. Furthermore, 
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activated T lymphocytes have been associated with diabetic nephropathy. One of the most 
striking features of leukocytes from patients with diabetes is the activated status of blood 
neutrophils. There is no doubt that immune cells participate in the vascular injury in the 
conditions of diabetic nephropathy, and their migration into the kidney is a crucial step in 
the progression of this disease [Galkina - 2006]. A few cross-sectional studies of individuals 
with type 1 diabetes have reported associations between increased albumin excretion rate 
and elevated levels of inflammatory markers including high-sensitivity (hs) C-reactive 
protein (CRP), soluble (s) tumor necrosis factor-ǂ receptor-1 (TNFR-1), intercellular 
adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), but 
whether the elevation of these inflammatory markers precedes nephropathy progression is 
not well described.  
Inflammatory cytokines and growth factors, mainly VEGF, TGF-ß, IL-1, IL-6, and IL-18, as 
well as TNF-ǂ, are also involved in the development and progression of DKD [Navarro-
Gonzales, 2008]. If inflammation contributes to the development of nephropathy, it would 
represent a potential therapeutic target for slowing the microvascular and macrovascular 
complications of diabetes [Lin, 2008]. 
6.10 Anemia 
Anemia is a common finding in patients with diabetes, particularly in those with overt 
nephropathy or renal impairment. Anemia in patients with diabetes is not restricted to those 
with renal impairment, as about half have normal renal function. Failure to up-regulate 
erythropoietin production in response to a declining hemoglobin level has been suggested 
to be the primary mechanism leading to chronic anemia. Accordingly, the presence of 
anemia may be a distinctive marker for renal tubulointerstitial dysfunction even before 
overt nephropathy manifests [Luk, 2008]. The precise mechanisms by which diabetes 
impairs the renal erythropoietin response to reduced Hb remain to be established. While 
functional erythropoietin deficiency is clearly linked to renal dysfunction in diabetes, the 
reduction in synthesis of erythropoietin in response to anemia appears to be beyond that 
seen in other renal (and particularly glomerular) diseases. A number of mechanisms 
potentially contribute to the preferential development of anemia in patients with diabetes. 
For example, the predominance of damage to specific cells and to the vascular architecture 
of the renal tubulo-interstitium, and the resulting systemic inflammation, autonomic 
neuropathy, and induction of inhibitors of erythropoietin release, have all been suggested as 
contributors to impaired renal erythropoietin production and release [Thomas, 2006]. 
Although anemia can be considered a marker of kidney damage, reduced hemoglobin levels 
independently identify diabetic patients with an increased risk of microvascular 
complications, cardiovascular disease and mortality. Nevertheless, a direct role in the 
development or progression of diabetic complications remains to be clearly established and 
the clinical utility of correcting anemia in diabetic patients has yet to be demonstrated in 
randomized controlled trials. Correction of anemia certainly improves performance and 
quality of life in diabetic patients [Thomas, 2007]. 
6.11 Hyperuricemia 
Uric acid has been associated with renal disease, even though hyperuricemia may be a 
marker of or by itself be responsible for microvascular disease in diabetes. In animal models, 
elevated level of uric acid can lead to arteriolopathy of preglomerular vessels, impaired 
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autoregulation, glomerular hypertension, as well as endothelial dysfunction. Kidney 
damage in hyperuricemic rats is not dependent on blood pressure, and instead involves the 
renin-angiotensin system. In patients with diabetes, serum uric acid early in the course of 
diabetes is significantly, and independent of confounders, associated with later 
development of persistent macroalbuminuria. Therefore, uric acid may be a novel and 
important player in the pathogenesis of microvascular complications in diabetes. A dose-
response relationship between serum uric acid and early decline in renal function has 
recently been demonstrated in patients with type-1 diabetes [Hovind, 2011].  
6.12 Aldosterone  
Another deleterious factor that has been underappreciated until recently is aldosterone. In 
addition to the classic effects of promoting sodium retention and volume expansion, 
aldosterone promotes inflammation, production of cytokines, growth factors and 
endothelial dysfunction, which acts on the renal vasculature, glomeruli and tubules and 
favors the emergence of proteinuria. In the setting of diabetes and longstanding 
hyperglycemia, free amino groups of proteins are non-enzymatically modified by glucose 
and its metabolites to form Schiff bases that eventually lead to the formation of advanced 
glycation end products (AGEs).  
6.13 The use of oral contraceptives 
Oral contraceptive (OC) use is associated with increased intrarenal renin–angiotensin–
aldosterone system (RAA System) activity and risk of nephropathy, though the contribution 
of progestins contained in the OC in the regulation of angiotensin-dependent control of the 
renal circulation has not been elucidated [Sarna, 2009]. 
7. Pathogenic mechanisms 
Multiple mechanisms contribute to the development and outcomes of diabetic nephropathy, 
such as an interaction between hyperglycemia induced metabolic and hemodynamic 
changes and genetic predisposition, which sets the stage for kidney injury [Dronavalli - 
2008]. Extracellular matrix accumulation is one of the hallmarks in the development of the 
disease that leads to the formation of glomerular and interstitial lesions [Deckert, 1981]. 
Multiple biochemical pathways have been postulated that explain how hyperglycemia 
causes tissue damage: nonenzymatic glycosylation that generates advanced glycosylation 
end products, activation of protein kinase C, and acceleration of the polyol pathway.  
8. Increased advanced glycation end products (AGEs) 
Advanced glycation end products (AGEs) are diverse group of molecules and are well 
known heterogeneous compounds formed nonenzymatically through an interaction of 
reducing sugar with free amino group of proteins, lipids and nucleic acids [Krishan, 2010]. 
AGEs form at a constant rate in the normal body; however, in diabetes, this process is 
drastically increased. Accumulation of AGEs in the kidney may contribute to the 
progressive alteration in renal architecture and loss of renal function in patients and rodents 
via various mechanisms, including their cross-linking properties of matrix proteins and 
activation of the downstream signaling. AGEs may produce functional changes in the 
kidney by cross-linking with the glomerular basement membrane and other vascular 
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membranes. AGE binding proteins may also be involved. The best defined is the receptor 
for AGEs (RAGE). Three main consequences have been found in association with AGEs 
inside cells: (1) functional alterations of intracellular proteins, (2) altered interaction with 
AGE receptors, and (3) altered interactions with matrix and other cells. Binding of AGEs to 
RAGEs activates cell signaling mechanisms coupled to increased transforming growth 
factor-ß (TGF-ß) and vascular endothelial growth factor (VEGF) expression, which are 
increased in diabetic nephropathy and are thought to contribute to diabetes complications. 
8.1 Increased transforming growth factor ß1  
Studies in rodent models have suggested that reduction in renal transforming growth factor 
(TGF)-ǃ1 may underlie the renoprotective effects of the renin-angiotensin system (RAS) 
blockade [Langham, 2006]. Over the past several years, experimental evidence consistently 
has suggested a key role for TGF-ǃ in the pathogenesis of the extracellular matrix 
accumulation that characterizes diabetic nephropathy and closely correlates with declining 
renal function [Mauer, 1984]. Angiotensin II potently induces synthesis of transforming 
growth factor (TGF)-ǃ, a profibrotic growth factor consistently implicated in the 
pathogenesis of diabetic nephropathy [Border, 1996]. The mechanisms for this fibrogenic or 
prosclerotic action of TGF-ǃ are multiple and include both stimulation of extracellular 
matrix synthesis and inhibition of its degradation [Bruijn, 1996]. 
8.2 Activation of protein kinase Cß (PKCß) 
Other proposed mechanisms by which hyperglycemia promotes the development of 
diabetic nephropathy include activation of PKC that involves de novo formation of 
diacylglycerol and oxidative stress. Hyperglycemia also increases the generation of 
advanced products of nonenzymatic glycosilation of proteins through activation of aldol 
reductase pathway and protein kinase C (PKC). The final products of non-enzymatic 
glycosilation are bound to collagen and proteins that constitute the glomerular basement 
membrane and make the glomerular barrier more permeable to the passage of proteins, 
resulting in increased urinary albumin excretion [Zelmanovitz, 2009]. Two clinical 
observations explain the possible mechanisms involved. The first is that the hyperglycemic 
state seems to sensitize the endothelium to injury from elevated blood pressure. The second 
observation is that successful pancreas transplant that results in normal insulin regulation 
and normoglycemia is associated with a reversal of the lesions of diabetic nephropathy 
[Lurbe, 2002]. Specifically, activation of this enzyme leads to increased secretion of 
vasodilatory prostanoids, which contributes to glomerular hyperfiltration. By activation of 
TGF-ǃ1, PKC might also increase production of extracellular matrix by mesangial cells. PKC 
activation induces the activity of mitogen-activated protein kinases (MAPK) in response to 
extracellular stimuli through dual phosphorylation at conserved threonine and tyrosine 
residues. The coactivation of PKC and MAPK in the presence of high glucose concentrations 
indicates that these two families of enzymes are linked [Dronavalli, 2008]. 
8.3 Aldose reductase pathway/polyol pathway 
Aldose reductase (AR) is a monomeric reduced nicotinamide adenine dinucleotide (NAD) 
phosphate (NADPH)-dependent enzyme and a member of aldo-keto reductase superfamily. 
Aldose reductase (AR) is widely expressed aldehyde-metabolizing enzyme. The polyol 
pathway is implicated in the pathogenesis of diabetic nephropathy. A number of studies 
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have shown a decrease in urinary albumin excretion in animals administered aldose 
reductase inhibitors, but in humans these agents have not been studied widely and the 
results are inconclusive [Tilton, 1989]. The reduction of glucose by the AR-catalyzed polyol 
pathway has been linked to the development of secondary diabetic complications 
[Srivastava - 2005]. 
8.4 The protein kinase C (PKC) pathway 
The protein kinase C (PKC) superfamily comprises proteins that are activated in response to 
various pathogenic stimuli in the diabetic state. Hyperglycemia is the predominant stimulus 
that induces the activation of distinct PKC isoforms within a cell, each mediating specific 
functions, probably through differential subcellular localization. Craven and DeRubertis 
[Craven, 1989] and Lee et al. [Lee, 1989] were the first to provide data indicating that 
activation of the PKC system by hyperglycemia may represent an important pathway by 
which glucotoxicity is transduced in susceptible cells in diabetic nephropathy. The putative 
intracellular mechanism is the glucose induced de novo synthesis of diacylglycerol that is 
one of the intracellular activators of PKC [Menne, 2009]. PKC activation is involved in the 
regulation of vascular permeability and contractility, endothelial cell activation and 
vasoconstriction, extracellular matrix (ECM) synthesis and turnover, abnormal 
angiogenesis, excessive apoptosis, leukocyte adhesion, abnormal growth factor signaling 
and cytokine action, as well as abnormal cell growth and angiogenesis, all of which are 
involved in the pathophysiology of diabetic vascular complications [Meier, 2009]. 
8.5 Vascular endothelial growth factor (VEGF) pathway 
Vascular endothelial growth factor (VEGF) is a key regulator of vascular permeability and 
angiogenesis and is implicated in the pathogenesis of diabetic retinal neovascularisation. In 
the glomerulus it is produced in large amounts by podocytes and is thought to be important 
in maintaining glomerular endothelial cell fenestrations [Satchell, 2006]. Hyperglycemia 
increases the expression of vascular endothelial growth factor (VEGF) in podocytes causing 
increased vascular permeability. VEGF has the potential to induce the new vessel growth 
seen in early diabetic nephropathy and to alter the permeability characteristics of the 
endothelium [Kanesaki, 2005]. In human type 1 diabetes, serum VEGF concentrations vary 
according to glycemic control, and higher levels are associated with microvascular 
complications, including microalbuminuria [Chiarelli, 2000]. In type 2 diabetes, VEGF is 
upregulated early in the course of disease and urinary VEGF levels are correlated with 
microalbuminuria [Kim, 2005]. Further studies have confirmed initial upregulation of VEGF 
signalling in type 2 diabetes followed by a down-regulation with podocyte loss and sclerosis 
development [Hohenstein, 2006].  
8.6 Oxidative stress pathway 
A large body of evidence indicates that oxidative stress is the common denominator link for 
the major pathways involved in the development and progression of diabetic micro- as well 
as macrovascular complications of diabetes nephropathy. Both hyperglycemia and 
activation of the renin-angiotensin system play a role in the generation of reactive oxygen 
species (ROS) [Anjaneyulu, 2004]. There are a number of macromolecules that have been 
implicated for increased generation of reactive oxygen species (ROS), such as, NAD(P)H 
oxidase, advanced glycation end products (AGE), defects in polyol pathway, uncoupled 
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nitric oxide synthase (NOS) and mitochondrial respiratory chain via oxidative 
phosphorylation. Excess amounts of ROS modulate activation of protein kinase C, mitogen-
activated protein kinases, and various cytokines and transcription factors which eventually 
cause increased expression of extracellular matrix (ECM) genes with progression to fibrosis 
and end stage renal disease. Activation of renin-angiotensin system (RAS) further worsens 
the renal injury induced by ROS in diabetic nephropathy. Buffering the generation of ROS 
may represent a promising therapeutic to ameliorate renal damage from diabetic kidney 
disease; however, various studies have demonstrated minimal reno-protection by these 
agents [Kashihara - 2010]. These derangements, along with hemodynamic changes, activate 
various cytokines and growth factors such as vascular endothelial growth factor, 
transforming growth factor-ǃ, Interleukin 1 (IL 1), IL-6 and IL-18. 
8.7 The activation of the transcription factor NF-kB  
Patients with diabetic kidney disease have higher monocyte NFκB activity than diabetic 
patients without renal complications. The transcription factor NF-kB helps to control the 
expression of numerous genes activated during inflammation. NF-kB is induced by various 
cell stress–associated stimuli including growth factors, vasoactive agents, cytokines, and 
oxidative stress. NF-kB in turn controls the regulation of genes encoding proteins involved 
in immune and inflammatory responses (i.e., cytokines, chemokines, growth factors, 
immune receptors, cellular ligands, and adhesion molecules) [Schmid - 2006]. Inhibition of 
NFκB reduces interstitial monocyte infiltration in rats with proteinuria, and NFκB is 
believed to play a key role in proteinuria-induced tubulointerstitial damage in diabetes 
[Remuzzi, 1998]. 
9. The histological changes 
Three major histological changes occur in the glomeruli of persons with diabetic kidney 
disease. First, mesangial expansion is directly induced by hyperglycemia, perhaps via 
increased matrix production or glycosylation of matrix proteins. Second, thickening of the 
glomerular basement membrane occurs. Third, glomerular sclerosis is caused by 
intraglomerular hypertension (induced by dilatation of the afferent renal artery or from 
ischemic injury induced by hyaline narrowing of the vessels supplying the glomeruli). These 
different histological patterns appear to have similar prognostic significance. All of these are 
part and parcel of microvascular complications of diabetes. A large body of evidence 
indicates that oxidative stress is the common denominator link for the major pathways 
involved in the development and progression of diabetic micro- as well as macro-vascular 
complications of diabetes. 
Light microscopy findings show an increase in the solid spaces of the tuft, most frequently 
observed as coarse branching of solid (positive periodic-acid Schiff reaction) material 
(diffuse diabetic glomerulopathy). Large cellular accumulations also may be observed 
within these areas. These are circular on section and are known as the Kimmelstiel-Wilson 
lesions/nodules.  
Electron microscopy provides a more detailed definition of the structures involved. In 
advanced disease, the mesangial regions occupy a large proportion of the tuft, with 
prominent matrix content. Further, the basement membrane in the capillary walls (ie, the 
peripheral basement membrane) is thicker than normal. Immunofluorescence microscopy 
may reveal deposition of albumin, immunoglobulins, fibrin, and other plasma proteins 
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along the GBM in a linear pattern most likely as a result of exudation from the blood vessels, 
but this is not immunopathogenetic or diagnostic and does not imply an immunologic 
pathophysiology. The renal vasculature typically displays evidence of atherosclerosis, 
usually due to concomitant hyperlipidemia and hypertensive arteriosclerosis.    
The severity of diabetic glomerulopathy is estimated by the thickness of the peripheral 
basement membrane and mesangium and matrix expressed as a fraction of appropriate 
spaces (eg, volume fraction of mesangium/glomerulus, matrix/mesangium, or 
matrix/glomerulus). The glomeruli and kidneys are typically normal or increased in size 
initially, thus distinguishing diabetic nephropathy from most other forms of chronic renal 
insufficiency, wherein renal size is reduced (except renal amyloidosis and polycystic kidney 
disease).  
10. Clinical diagnosis of diabetic kidney disease  
The clinical diagnosis of diabetic kidney disease is, mainly, based on detection of 
albuminuria from spot urine is recommended because the albumin-creatinine ratio by spot 
urine sample has demonstrated excellent correlation with the 24-hour urine albumin 
measurements. Estimated glomerular filtration rate (eGFR), has been added to the 
albuminuria also as a renal biomarker. Both are indeed associated with renal and 
cardiovascular disease in individuals with diabetes and may be used to identify individuals 
at risk of long-term complications. 
Microalbuminuria, which is an indicator of endothelial dysfunction, and an independent 
marker for cardiovascular morbidity and mortality in individuals with and without diabetes 
is defined as an albumin-creatinine ratio of 30-300 mg/g from a spot urine collection, 
urinary albumin excretion 30-300 mg/24 hours in a 24-hour urine collection, or 20-200 
µg/min in a timed urine collection. 
Macroalbuminuria is defined as an albumin/creatinine ratio (ACR) > 300 mg/g from a spot 
urine collection, urinary albumin excretion > 300 mg/24 hours in a 24-hour urine collection, 
or >200 µg/min in a timed urine collection. For initial screening of diabetic kidney disease, 
the measurement of albuminuria from spot urine is recommended because the ACR by spot 
urine sample has demonstrated excellent correlation with the 24-hour urine albumin 
measurements. 
If the determination of albuminuria cannot be performed at diagnosis, we can measure 
proteinuria. Microproteinuria is defined by a value between 300-500 mg/24 hours and 
macroproteinuria is defined by a value higher than 500 mg/24 hours. Serum markers of 
glomerular filtration rate and microalbuminuria identify renal impairment in different 
segments of the diabetic population, indicating that serum markers as well as 
microalbuminuria tests should be used in screening for nephropathy in diabetic patients.  
There is accumulating evidence suggesting that the risk for developing diabetic nephropathy 
and cardiovascular disease starts when UAE values are still within the normoalbuminuric 
range [Gerstein, 2001]. After the diagnosis of micro- or macroalbuminuria is confirmed, 
patients should undergo a complete evaluation, including a work-up for other etiologies and 
an assessment of renal function and the presence of other comorbid associations [Gross - 2005]. 
10.1 Glomerular filtration rate 
Although the best measure for glomerular filtration rate (GFR) is obtained by techniques 
that involve infusion of exogenous substances, GFR is usually estimated in clinical practice 
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by various formulae based on serum creatinine concentration, since this is much less 
invasive and time-consuming. The most popular equation used today is the Modification of 
Diet in Renal Disease (MDRD) equation [Levey, 1999 ]. 
Recent efforts to identify novel biomarkers in the diabetic population have been evolving 
either to detect early kidney injury or repair that ultimately lead to progression of diabetic 
kidney disease. 
10.2 Cystatin-C 
Cystatin-C, a cysteine protease inhibitor that is produced by virtually all nucleated cells and 
released into the bloodstream is entirely filtered by the kidney glomerulus and metabolized 
by the proximal tubule. Recently interest has developed in cystatin-C and was proposed as a 
potential endogenous filtration marker of GFR because it is a more sensitive indicator of 
mild renal impairment and may better estimate the GFR than serum creatinine. 
10.3 Retinol-binding protein 4 (RBP-4)  
Retinol-binding protein 4 (RBP-4) is a small visceral protein, mainly synthesized in the liver 
and catabolized in the kidneys after glomerular filtration. Initially reported as an adipokine 
that impairs insulin sensitivity, the concentrations of this adipokine are increased in diabetic 
patients as compared to normal subjects.  
Mechanistic studies have suggested that RBP-4 impaired insulin sensitivity by inhibition of 
insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activation in 
muscle and by induction of glucose production in liver via cytosolic phosphoenolpyruvate 
carboxykinase (PEPCK) stimulation [Yang, 2005]. Interestingly, urinary RBP-4 excretion is 
increased in early diabetic nephropathy and might even be a marker of early renal damage 
preceding microalbuminuria [Hong, 2000]. 
10.4 Connective tissue growth factor (CTGF)  
Connective tissue growth factor (CTGF) is a polypeptide with functions in extracellular 
matrix production and other profibrotic activity mediated by transforming growth factor-ǃ1. 
Other biological functions of CTGF include angiogenesis, chondrogenesis, osteogenesis, and 
cell adhesion, migration, proliferation, and differentiation. The upregulation of CTGF has 
been observed in human and experimental diabetic nephropathy. 
10.5 Pigment epithelium-derived factor (PEDF) 
Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily 
of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, 
anti-oxidative and anti-inflammatory properties, any of which could potentially be 
exploited as a therapeutic option for the treatment of vascular complications in diabetes. 
Recent studies suggest that PEDF could reduce proteinuria by suppressing podocyte 
damage and decreased nephrin as well as increased VEGF expression in the glomeruli of 
ADN rats. It has been reported that PEDF counteracts the effects of VEGF [Liu, 2004] and 
advanced glycation end products [Inagaki, 2003]. It is noteworthy in the future to determine 
whether PEDF may be used as a specific marker for screening incipient DN. 
10.6 Pentoxifylline (PTF)  
Pentoxifylline (PTF) is a methylxanthine derivative with favorable effects on microcirculatory 
blood flow as a result of its rheological properties. Recent studies have shown that PTF 
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reduces urinary protein excretion in individuals with diabetes, both with normal renal 
function and with renal insufficiency. In a previous study in patients with diabetes and 
nephropathy, was found that TNF-ǂ concentrations were significantly elevated and related to 
the urinary protein excretion and, moreover, that the levels of this cytokine decreased after 
PTF administration, with a significant correlation between the decrease of TNF-ǂ and the 
reduction of proteinuria. It was demonstrated in rats that Pentoxifylline reduces the 
accumulation and proliferation of glomerular macrophages in mesangial proliferative 
glomerulonephritis, and the recruitment of macrophages, lymphocytes, and major 
histocompatibility complex (MHC) class II antigen-positive cells into remnant kidney 
interstitium [Lin, 2002]. 
Emerging roles of urinary biomarkers have proven beneficial due to the ability to 
standardize the various markers to creatinine or peptides already present in the urine. The 
role of neutrophil gelatinase-associated lipoprotein, kidney injury molecule-1 and podocin 
derivatives have gained enormous significance in the process of early identification of 
kidney injury in the diabetic population [Buddineni - 2011]. 
11. Differential diagnosis 
Differential diagnosis is usually based on the history, physical examination, laboratory 
evaluation, and imaging of the kidneys. Renal biopsy is only recommended in special 
situations. The diagnosis of diabetic nephropathy is easily established in long-term type 1 
diabetic patients (>10 years diabetes duration), especially if retinopathy is also present. 
Typical diabetic nephropathy is also likely to be present in proteinuric type 2 diabetic 
patients with retinopathy. However, diagnostic uncertainty exists in some patients with 
type 2 diabetes since the onset of diabetes is unknown and retinopathy is absent in a 
significant proportion (28%) of these patients [Christensen, 2001]. 
Imaging of the kidneys, usually by ultrasonography, should be performed in patients with 
symptoms of urinary tract obstruction, infection, or kidney stones or with a family history of 
polycystic kidney disease [Levey, 2003]. 
12. Prevention and treatment of diabetic nephropathy 
Monitoring of type 2 diabetic patients for microalbuminuria at least once per year is 
recommended. Microalbuminuria in type 2 diabetic patients is not as potent a real risk 
predictor as in type 1 diabetic patients, but it is certainly the best available tool to identify 
patients in need of intensified treatment [Rugenetti, 1998].  
13. Glycemic and blood pressure control  
The interventions which proved to prevent the onset or attenuate the progression of diabetic 
nephropathy includes a combination of tight control of blood glucose (goal is < 7%), tight 
control of blood pressure (goal < 130/80 mmHg), lowering of urine albumin, and stopping 
of smoking (a well-established endothelial cell toxin that also affects progression of kidney 
disease), the specific blockage of the renin-angiotensin-aldosteron system (RAAS), with 
either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers 
(ARB) and lipid-lowering therapy, especially statins and fibrates.  
There is evidence that early therapeutic intervention in patients with chronic kidney disease 
or diabetes can delay onset of complications and improve outcomes [Atkins, 2010]. For 
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example, the UKPDS [Holman, 2008 Bilous, 2008], STENO-2 [Gaede, 2008], and ADVANCE 
studies [Patel, 2007, Patel, 2008, Zoungas, 2009]  demonstrated that tight control of blood 
glucose level, blood pressure (and lipids in STENO-2) significantly reduced incidence and 
progression of diabetic kidney disease. In people with type 2 diabetes, inhibition of the 
renin-angiotensin-aldosterone system using an ACE inhibitor or an ARB decreased the 
progression from normoalbuminuria to microalbuminuria [Ruggenenti, 2004], reduced the 
progression from micro albuminuria to macroalbuminuria, [Parving, 2001] and slowed the 
development of ESRD [Lewis, 2001]. Thus the use of an ACE inhibitor or ARB is now 
standard therapy for patients with diabetic nephropathy as well as glucose, lipid and blood 
pressure control. Effective management using evidence-based therapies is the fourth step in 
tackling diabetic kidney disease.   
Like other microvascular complications of diabetes, there are strong associations between 
glucose control (as measured by hemoglobin A1c [A1C]) and the risk of developing diabetic 
nephropathy. Patients should be treated to the lowest safe glucose level that can be obtained 
to prevent or control diabetic nephropathy [Fowler - 2008]. Glycemic control in both type 1 
and type 2 diabetes has been associated with reduced appearance of diabetic nephropathy 
(microalbuminuria) [Hall, 2006]. Control of glycemia in type 2 diabetic patients with 
nephropathy represents some peculiar aspects. Today there is no longer any doubt that tight 
glycemic control prevents the onset or progression of diabetic nephropathy in type 2 
diabetic patients as it does in type 1 diabetic patients. In the past, it had been thought that 
once clinically manifest nephropathy had developed, a point of no return was reached 
beyond which tight glycemic control failed to prevent the further decline in renal function. 
Nevertheless recent studies from the Steno Hospital showed that glycemic control had 
some, although less pronounced compared with tight BP control, effect on the rate of 
progression [Wolf, 2003]. 
The Diabetes Control and Complications Trial, the United Kingdom Prospective Diabetes 
Study and the Japanese Diabetes Intervention Study have confirmed that tight glycemic 
control can prevent the development of all microvascular complications including 
nephropathy [Looke, 2008]. 
Once albuminuria occurs, controlling blood pressure assumes critical importance. The use of 
renin–angiotensin blockade has been a major advance in the management of diabetic 
nephropathy. Major landmark studies including the Irbesartan Diabetic Nephropathy Trial 
[Louis, 2001] and RENAAL study [Brenner, 2001] have provided compelling evidence to 
support the renoprotective effect of angiotensin-II receptor antagonists, independent of 
blood pressure lowering [Looke, 2008]. 
The renin–angiotensin system (RAAS) is an important target for hemodynamic disturbances 
in diabetic kidney disease. Blocking the renin–angiotensin system in diabetes has 
pluripotent effects on modifying the systemic and glomerular hemodynamic as well as 
attenuating the pro-inflammatory and pro-fibrotic changes in renal parenchyma [Look, 
2008]. The pharmacological agents which block the RAAS slow the progression of renal 
dysfunction more effectively than other classes of antihypertensive agents. In addition to 
normalization of systemic and glomerular hypertension, it is now clear that inhibition of the 
RAAS at various levels have several renoprotective effects, including anti-inflammatory and 
antifibrotic mechanisms. 
Currently available therapies for this blockade are angiotensin converting enzyme inhibitor 
(ACE-I), angiotensin II type 1 receptor blocker (ARB) and direct renin inhibitor.  If the 
treatment with ACEI and/or ARB does not reach the blood pressure target levels, then they 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
262 
can be combined with other drug classes, even before maximizing the dose of each agent. 
The combination of agents may include calcium channel blockers (especially 
nondihydropyridine), ǃ-blockers, diuretics or central ǂ2-agonist.  
Another concept of a dual blockade of the RAAS has been developed by Mogensen in 2000. 
Since ACEI and ARB interrupt the RAAS at different levels, the combination of these classes 
of drugs may have an additive effect on renoprotection. The renoprotective effects of dual 
blockade of the RAAS with ARB and direct renin inhibitor (aliskiren) may also be effective. 
Addition of diuretics has been strongly recommended by KDOQI guidelines to achieve 
target blood pressures of < 130 mmHg in cases of recalcitrant hypertension in diabetes 
kidney disease patients. The role for aldosterone antagonist (spironolactone) and statins in 
prevention of metabolic derangements consequent to RAAS overactivity in DKD is 
emerging. 
The BP-lowering arm of the Action in Diabetes and Vascular disease: preterAx and 
diamicroN-MR Controlled Evaluation (ADVANCE) study recently reported that the routine 
administration of a fixed combination of the angiotensin converting enzyme inhibitor 
perindopril and the diuretic indapamide to a broad cross-section of patients with type 2 
diabetes reduced the risk for cardiovascular and kidney outcomes, regardless of initial BP 
level. More recently, the glucose-lowering arm of ADVANCE reported that intensive 
glucose lowering based on gliclazide (modified release) reduced the risk for new or 
worsening nephropathy. 
While good glycemic control ameliorates the development of microalbuminuria in type 1 
and type 2 diabetes there is increasing evidence that angiotensin-converting enzyme 
inhibition and angiotensin receptor blockade are ineffective as primary prevention 
strategies. Blood pressure control remains the mainstay of treating established diabetic renal 
disease and a multi-factorial intervention approach in those with type 2 diabetes and 
microalbuminuria appears to be effective in reducing mortality based on data from one 
study [Walker, 2010]. 
14. Aldosterone receptor antagonists 
Experimental studies supporting aldosterone antagonists have shown anti-inflammatory 
effect, anti-fibrotic properties and suppression of markers of tubular injury, interstitial 
fibrosis and glomerulosclerosis [Kramer, 2007]. Aldosterone antagonists have generally been 
considered to have an antiproteinuric effect, and addition of spironolactone to an ACE 
inhibitor or ARB is associated with a marked and sustained antiproteinuric effect, with the 
rate of hyperkalemia being similar to placebo. These results are based on studies with small 
numbers of patients, mostly of very short follow-up. There are no long term data regarding 
benefit with the combination of ACE inhibitor or ARB and aldosterone antagonists in terms 
of slowing the progression of diabetic kidney disease. In clinical practice, the use of this 
combination of agents in patients with low GFR should be undertaken with careful 
instructions for dietary potassium restriction and avoidance of nonsteroidal anti-
inflammatory drugs and cyclooxy-genase-2 inhibitors [Satirapoj, 2010]. 
15. Peroxisome proliferator-activated receptors (PPAR)-gamma agonists 
Peroxisome proliferator activated receptor-Ǆ (PPARǄ) is a ligand activated transcription 
factor that regulates cell growth, inflammation, lipid metabolism and insulin sensitivity, 
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appear to have a role in regulating adipogenesis and blood pressure [Satirapoj, 2010]. 
PPARǄ agonists may indirectly suppress the systemic production of a proinflammatory 
milieu mainly via inhibiting TNF-ǂ, PAI-1, and IL-6 expression in adipose tissue. 
Additionally, PPARǄ seems to have anti-inflammatory effects on monocytes. PPARǄ 
activation can reduce the production of cytokines (TNF-ǂ, IL-1, IL-6), probably through 
inhibiting the activity of proinflammatory transcription factors such as NF-κB. PPARs have 
also been implicated in many renal pathophysiological conditions, including diabetic 
nephropathy and glomerulosclerosis [Ruan, 2008]. Recently it was demonstrated that 
peroxisome proliferator activated receptor-Ǆ (PPARǄ) agonists block the deleterious effects 
of AGEs and exert beneficial actions on diabetic nephropathy. It has been successfully 
shown that PPAR-Ǆ agonists limit high glucose-induced inflammation in proximal tubular 
cells. PPAR-Ǆ agonists also exert anti-fibrotic effects in human proximal tubular cells under 
high glucose conditions by attenuating the increase in AP-1, TGF-ǃ1 and downstream 
production of the extracellular matrix protein, fibronectin. PPAR-Ǆ agonists can improve 
insulin sensitivity, reduce triglyceride levels and decrease the risk of atherosclerosis. PPARǄ 
agonists have been shown to lower blood pressure in animals and humans, perhaps by 
suppressing the renin-angiotensin (Ang)-aldosterone system (RAAS), including the 
inhibition of Ang II type 1 receptor expression, Ang-II-mediated signaling pathways, and 
Ang-II-induced adrenal aldosterone synthesis/secretion [Sugawara, 2011]. 
16. Protein restriction 
Animal studies have shown that restriction of dietary protein intake also reduces 
hyperfiltration and intraglomerular and retards the progression of several models of renal 
disease, including diabetic glomerulopathy. Reduction of dietary protein has long been 
proposed as a treatment for CRF and this intervention has shown a modest benefit in slowing 
loss of filtration function, but adherence to this form of therapy is difficult in diabetes. 
17. Lipid control 
Clinical studies in patients with diabetic nephropathy showed that lipid control can be 
associated with an additional effect of reduction in proteinuria. Lipid-lowering agents 
(statins) showed renoprotection in a variety of proteinuric glomerular diseases [Agarwal, 
2007]. Although lipid-lowering treatment has been shown to be effective in reducing 
cardiovascular morbidity and mortality in diabetic patients with hyperlipidemia, their 
effects on diabetic nephropathy are still unclear due to lack of prospective randomized 
intervention studies [Chen, 2005]. Early studies have demonstrated that treatment with the 
HMG CoA reductase inhibitor pravastatin decreases albuminuria in patients with type 2 
diabetes [Sasaki, 1990]. Experimental studies demonstrated that lipid-lowering agents 
exerted a certain degree of renoprotection, through both indirect effects from lipid lowering 
and a direct effect on cell protection. Therefore, lipid control appears to be important in the 
prevention and treatment of diabetic nephropathy [Chen, 2005]. 
18. Antioxidants 
There have been multiple trials using vitamin E, vitamin C, probucol, taurine, n-
acetylcysteine, lipoic acid, and other antioxidant drugs in animals. Animal studies using 
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these compounds have been shown to be effective in reducing the development of diabetic 
kidney disease. It’s hard to translate these animal results to humans as many trials in mice 
and rats are very effective in the particular animal but often ineffective in humans. This may 
be due to short duration of animal studies, dose differences between animals and humans, 
and different pathophysiologic processes between animals and humans. Human studies 
with antioxidants for diabetic nephropathy are limited and have had variable results 
[Stanton, 2011]. 
Despite receiving optimal care to control blood pressure and metabolic risk factors as well as 
inhibition of the renin–angiotensin system in a clinical trial setting, there is a considerable 
residual risk for cardio-renal complications in patients with diabetic kidney disease. 
Understanding the molecular milieu of diabetic podocyte injury, an early event in diabetic 
nephropathy, remains a primary target in identifying novel avenues for early intervention 
and prevention of severe late complications of this increasingly prevalent disease. 
Decreasing hyperglycemia's toxic effects, stimulating the endogenous protective factors, 
controlling obesity and low grade inflammation as well as correction of anemia may 
represent also areas where novel strategies can be developed and tested to curb this rising 
global burden of cardio-renal complications in diabetic patients. Correction of anemia 
improves renal tissue oxygenation, reduces hypoxic damage and associated oxidative stress. 
There have been several reports suggesting that early erythropoietin treatment may retard 
the progression of renal diseases and delay the commencement of renal replacement 
therapy.  
Annual screening for microalbuminuria will allow the identification of patients with 
nephropathy at a point very early in its course. Improving glycemic control, aggressive 
antihypertensive treatment, and the use of ACE inhibitors or ARBs will slow the rate of 
progression of nephropathy. In addition, protein restriction and other treatment modalities 
such as phosphate lowering may have benefits in selected patients. 
In conclusion, there are very compelling reasons to better understand the mechanisms 
underlying diabetic kidney disease, to develop new treatments that can both prevent the 
development of kidney disease and slow or stop the progression. 
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